Federal Circuit to Consider On-Sale Bar En Banc - The Medicines Company v. Hospira, Inc.

McDermott Will & Emery
Contact

Addressing the application of the on-sale bar under § 102(b), the U.S. Court of Appeals for the Federal Circuit, in The Medicines Company v. Hospira, Inc., Case Nos. 14-1469; 14-1504, found that the claims of an asserted patent covering “pharmaceutical batches” for making Angiomax (bivalirudin) by a new process were invalid based on an agreement, dated more than one year prior to the application filing date, to have a third party, Ben Venue Laboratories, prepare three batches according to the process (IP Update, Vol. 18, No. 8).

Now, the Federal Circuit has agreed to consider en banc the issue of what constitutes a “commercial offer for sale,” initiating the one-year patent application filing requirement.

Specifically, the Court has asked the parties to brief the following questions:

a. Do the circumstances presented here constitute a commercial sale under the on-sale bar of 35 U.S.C. §102(b)?
    i. Was there a sale for the purposes of § 102(b) despite the absence of a transfer of title?
    ii. Was the sale commercial in nature for the purposes of § 102(b) or an experimental use?
b. Should this court overrule or revise the principle in Special Devices, Inc. v. OEA, Inc., 270 F.3d 1353 (Fed. Cir. 2001), that there is no “supplier exception” to the on-sale bar of 35 U.S.C. §102(b)?

The Court specifically invited the U S Department of Justice to file a brief expressing the views of the United States as amicus curiae.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Written by:

McDermott Will & Emery
Contact
more
less

McDermott Will & Emery on:

Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.